IRADIMED (IRMD) Hisse Özeti
IRADIMED CORPORATION, manyetik rezonans görüntüleme (MRI) uyumlu intravenöz infüzyon pompa sistemleri ve MRI uyumlu hasta yaşamsal belirtileri izleme sistemleri ve ilgili aksesuarları geliştirir, üretir, pazarlar ve dağıtır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 2/6 |
IRMD Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IRADIMED CORPORATION Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$93.96 |
| 52 Haftanın En Yüksek Seviyesi | US$107.90 |
| 52 Haftanın En Düşük Seviyesi | US$55.11 |
| Beta | 0.92 |
| 1 Aylık Değişim | 3.64% |
| 3 Aylık Değişim | -1.04% |
| 1 Yıllık Değişim | 54.44% |
| 3 Yıllık Değişim | 96.82% |
| 5 Yıllık Değişim | 216.90% |
| Halka arzdan bu yana değişim | 849.09% |
Son Haberler & Güncellemeler
Analiz Makalesi • Jun 22
IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative
With no single headline event driving attention to IRADIMED (IRMD) today, investors are instead looking at the stock’s recent performance record and financial profile to reassess how it fits into a healthcare portfolio. See our latest analysis for IRADIMED. IRADIMED’s share price has been choppy in recent months, with the stock down around 7% over 90 days and 3% year to date, yet its 1 year total shareholder return of about 61% and 5 year total shareholder return above 250% still point to...
Anlatı Güncellemesi • Jun 18
IRMD: 2026 Guidance And Bullish Initiation Will Drive Further Re Rating
Analysts have maintained their $118 price target on IRADIMED, citing recent bullish initiation and supporting research that highlight the company's long-term earnings potential, along with a still-elevated forward P/E profile. What’s in the News for IRADIMED IRADIMED issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.0 million to US$21.0 million and GAAP diluted EPS between US$0.40 and US$0.44.Anlatı Güncellemesi • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Recent updates
Analiz Makalesi • Jun 22
IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative
With no single headline event driving attention to IRADIMED (IRMD) today, investors are instead looking at the stock’s recent performance record and financial profile to reassess how it fits into a healthcare portfolio. See our latest analysis for IRADIMED. IRADIMED’s share price has been choppy in recent months, with the stock down around 7% over 90 days and 3% year to date, yet its 1 year total shareholder return of about 61% and 5 year total shareholder return above 250% still point to...Anlatı Güncellemesi • Jun 18
IRMD: 2026 Guidance And Bullish Initiation Will Drive Further Re Rating
Analysts have maintained their $118 price target on IRADIMED, citing recent bullish initiation and supporting research that highlight the company's long-term earnings potential, along with a still-elevated forward P/E profile. What’s in the News for IRADIMED IRADIMED issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.0 million to US$21.0 million and GAAP diluted EPS between US$0.40 and US$0.44.Anlatı Güncellemesi • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Anlatı Güncellemesi • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Anlatı Güncellemesi • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Anlatı Güncellemesi • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Anlatı Güncellemesi • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Anlatı Güncellemesi • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Anlatı Güncellemesi • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Anlatı Güncellemesi • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Anlatı Güncellemesi • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Anlatı Güncellemesi • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Anlatı Güncellemesi • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Anlatı Güncellemesi • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Anlatı Güncellemesi • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Analiz Makalesi • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Analiz Makalesi • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Analiz Makalesi • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Yeni Anlatı • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Analiz Makalesi • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Analiz Makalesi • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analiz Makalesi • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analiz Makalesi • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analiz Makalesi • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Analiz Makalesi • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Hissedar Getirileri
| IRMD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 1.9% | 3.9% | -2.5% |
| 1Y | 54.4% | -19.9% | 19.0% |
Getiri vs. Endüstri: IRMD geçen yıl % -19.9 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: IRMD geçen yıl % 19 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| IRMD volatility | |
|---|---|
| IRMD Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: IRMD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: IRMD 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1992 | 166 | Roger Susi | www.iradimed.com |
IRADIMED CORPORATION, manyetik rezonans görüntüleme (MRI) uyumlu intravenöz infüzyon pompa sistemleri ve MRI uyumlu hasta yaşamsal belirti izleme sistemleri ve ilgili aksesuarları geliştirir, üretir, pazarlar ve dağıtır. Şirket, MRidium 3870 ve 3860+ MRI Uyumlu IV İnfüzyon Pompa Sistemi ile ilişkili tek kullanımlık IV hortum setleri; 3880 MRI uyumlu hasta yaşamsal belirtileri izleme sistemi; ve uzaktan alarm kayıt ünitesi ferromanyetik algılama cihazına sahip 3600 FMD1 sunmaktadır. Ayrıca manyetik olmayan IV kutupları, kablosuz uzak ekranlar/kontroller, yan araba pompa modülleri, doz hatası azaltma sistemleri ve sensörler ve aksesuarlarla SpO2 izleme sağlar.
IRADIMED CORPORATION Temel Bilgiler Özeti
| IRMD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.20b |
| Kazançlar(TTM) | US$23.61m |
| Gelir(TTM) | US$86.28m |
50.9x
F/K Oranı13.9x
P/S OranıIRMD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| IRMD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$86.28m |
| Gelir Maliyeti | US$19.99m |
| Brüt Kâr | US$66.30m |
| Diğer Giderler | US$42.68m |
| Kazançlar | US$23.61m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 1.85 |
| Brüt Marj | 76.84% |
| Net Kâr Marjı | 27.36% |
| Borç/Özkaynak Oranı | 0% |
IRMD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.9%
Mevcut Temettü Verimi40%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/28 05:54 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
IRADIMED CORPORATION 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |